ReviewNature2018
The emergence of Zika virus and its new clinical syndromes.
Review in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 263 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
263 citing papers in PubMed, 3 syntheses or guidelines pooled it, 404 citations in OpenAlex.
- The worldwide seroprevalence of DENV, CHIKV and ZIKV infection: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Measuring the global burden of chikungunya and Zika viruses: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Update on the Transmission of Zika Virus Through Breast Milk and Breastfeeding: A Systematic Review of the Evidence.Viruses · 2021Pooled it
- Comparative analysis of flavivirus sfRNA dynamics and secondary structure.Journal of virology · 2026Article
- Reprogramming lipid metabolism in virus-infected neuronal cells.Research square · 2026Article
- The nucleoside analog CMX521 inhibits coronavirus RNA-dependent RNA polymerase via a two-pronged mechanism.bioRxiv : the preprint server for biology · 2026Article
- Design and development of N-Heterocyclic protease inhibitors for flaviviral infections: a synthetic and SAR-based review.Molecular diversity · 2026Review
- PTBP1 is upregulated in response to Zika virus infection and restrains viral replication by hijacking viral NS1 protein to induce NS1 degradation.Journal of virology · 2026Article
- Targeting the Zika virus envelope domains I and III as a recombinant vaccine protects mice from lethal challenge.NPJ vaccines · 2026Article
- Comparative analysis of flavivirus sfRNA dynamics and secondary structure.bioRxiv : the preprint server for biology · 2026Article
- STING agonists as antiviral agents.FEBS letters · 2026Review
- Article
- Interferon lambda signaling to maternal dendritic cells protects against congenital Zika virus infection.bioRxiv : the preprint server for biology · 2026Article
- FcγRIIA signalling as a host-associated determinant of endosomal trafficking and antibody-dependent enhancement in flavivirus infection.Frontiers in immunology · 2026Article
- Vertical Transmission of Zika Virus: The Immune-Pathophysiological Interface of the Placenta.Journal of immunology research · 2026Review
- Clinical metagenomics for diagnosis and surveillance of viral pathogens.Nature reviews. Microbiology · 2026Review
- Generation and characterization of an anti ITGB4 monoclonal antibody that blocks Zika virus entry.Frontiers in immunology · 2026Article
- ZIKV infection causes placental inflammation through activating PANoptosis.Journal of virology · 2025Article
- Assessment of Hairpin-Functionalization of Gold Nanoparticles toward a Facile Detection of Zika Virus and Lineage Identification.ACS omega · 2025Article
- Intracranial injection of genetically modified, mosquito non-transmissible Zika virus: Safety in primates and ramifications for brain tumor therapy.Cell reports. Medicine · 2025Article
203 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Zika virus (ZIKV) is a mosquito-transmitted flavivirus that has emerged as a global health threat because of its potential to generate explosive epidemics and ability to cause congenital disease in the context of infection during pregnancy. Whereas much is known about the biology of related flaviviruses, the unique features of ZIKV pathogenesis, including infection of the fetus, persistence in immune-privileged sites and sexual transmission, have presented new challenges. The rapid development of cell culture and animal models has facilitated a new appreciation of ZIKV biology. This knowledge has created opportunities for the development of countermeasures, including multiple ZIKV vaccine candidates, which are advancing through clinical trials. Here we describe the recent advances that have led to a new understanding of the causes and consequences of the ZIKV epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.